Loading stock data…
Telomir Pharmaceuticals, Inc. (TELO)
$1.19+0.03 (+2.59%)
Market ClosedLast close Sep 8
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Telomir Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.19 with a market capitalization of $86M. The stock is currently 43% below its 52-week high of $2.09, remaining 6.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.19M↑ | -$5.07M↓ | -$1.15M↑ | -$2.13M↓ | -$1.04M |
| Net Income | -$2.18M↑ | -$5.07M↓ | -$1.10M↑ | -$2.06M↓ | -$990,947 |
Peer Comparison
JNJUNHPFE
Fundamentals
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-185.89%
Volume
Today's trading volume
74,906